Molecular Profiling of Exceptional Responders to Cancer Therapy.

ABSTRACT:

Background

The vast majority of metastatic cancers cannot be cured. Palliative treatment may relieve disease symptoms by stopping or slowing cancer growth and may prolong patients' lives, but almost all patients will inevitably develop disease progression after initial response. However, for reasons that are not fully understood, a very few patients will have extraordinary durable responses to standard anticancer treatments.

Materials and methods

We analyzed exceptional responders treated at Fox Chase Cancer Center between September 2009 and November 2017. An exceptional response was defined as a complete response lasting more than 1 year or a partial response or stable disease for more than 2 years. Tumor samples were analyzed using an Ambry Genetics test kit with a 142-gen

SUBMITTER: Bilusic M 

PROVIDER: S-EPMC7930427 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature